ArticleFrontiers in oncology2024

Case report: Precise NGS and combined bevacizumab promote durable response in ALK-positive lung adenocarcinoma with multiple-line ALK-TKI resistance.

Jin Xiong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.